Online citations, reference lists, and bibliographies.
← Back to Search

Evidence Of RNAi In Humans From Systemically Administered SiRNA Via Targeted Nanoparticles

M. Davis, Jonathan E Zuckerman, C. Choi, D. Seligson, A. Tolcher, C. Alabi, Y. Yen, J. Heidel, A. Ribas
Published 2010 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response. We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.
This paper references
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent anti-viral strategy
R Alvarez (2009)
10.1038/nchembio839
RNAi therapeutics: a potential new class of pharmaceutical drugs
D. Bumcrot (2006)
10.1038/35078107
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Sayda M. Elbashir (2001)
10.1128/AAC.00014-09
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
R. Alvarez (2009)
10.1038/mt.2009.273
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.
S. Leachman (2010)
10.1038/nature07758
The promises and pitfalls of RNA-interference-based therapeutics
D. Castanotto (2009)
10.1007/s10238-007-0125-z
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
M. Koldehoff (2007)
10.1038/35888
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
A. Fire (1998)
10.1093/nar/gkj439
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
D. Bartlett (2006)
10.1002/BIT.21668
Impact of tumor‐specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA‐containing nanoparticles
D. Bartlett (2008)
an appealing target in anti-tumor therapy
Cerqueira (2005)
10.1038/nature06765
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
M. Kleinman (2008)
The measured resolution at which images were acquired is 512 3 512 pixels, and the image bit-depth is 8-bit. The Zeiss LSM Image Browser Software allows the extraction of images
10.1038/ng944
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice
D. L. Lewis (2002)
Patient RNA samples were reversed-transcribed using SuperScriptIII reverse transcriptase. White blood cell (WBC) cDNA (0.4–200 ng) was used as a
Qrt
10.1021/mp900015y
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
M. Davis (2009)
10.1073/pnas.0905487106
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements
Thomas Schluep (2009)
10.2174/0929867054020981
Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy.
N. A. Cerqueira (2005)
from concept to clinic
Davis (2009)
Au-PEG-AD staining of CALAA-01 nanoparticles in tumor biopsy samples using Au-PEG-AD and DAPI nuclear counter-stain. All pre-treatment samples
-Peg-Ad Dapi Au
10.1158/1078-0432.CCR-06-2218
Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo
J. Heidel (2007)
Supplementary Information is linked to the online version of the paper at www.nature.com/nature
10.1073/pnas.0701458104
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
J. Heidel (2007)
10.1038/nature03121
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J. Soutschek (2004)
California 91010, USA. 7 Calando Pharmaceuticals, 201 South Lake Avenue, Suite 703
10.1073/pnas.0707461104
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)
10.1038/nm828
RNA interference targeting Fas protects mice from fulminant hepatitis
E. Song (2003)
10.1136/jcp.36.5.539
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
K. Gatter (1983)
10.1016/j.antiviral.2007.11.009
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).
J. Devincenzo (2008)
RNA interference in adult mice
A P Mccaffrey (2002)
10.3892/OR.15.5.1299
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
A. Juhász (2006)
10.1007/BF00395486
Comparative studies on the ultrastructure of malignant melanoma in fish and human by freeze-etching and transmission electron microscopy
R. Riehl (2004)
10.1021/BI00398A068
Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line.
G. McClarty (1987)



This paper is referenced by
10.1021/nn301725w
PSMA-targeted theranostic nanoplex for prostate cancer therapy.
Z. Chen (2012)
10.1039/c0mt00095g
Metal use in ribonucleotide reductase R2, di-iron, di-manganese and heterodinuclear--an intricate bioinorganic workaround to use different metals for the same reaction.
M. Högbom (2011)
10.1016/j.addr.2013.05.001
Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.
J. Zhang (2013)
10.1016/j.msec.2017.03.124
Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
A. Suo (2017)
10.7150/thno.5113
Multicolor Upconversion Nanoparticles for Protein Conjugation
S. Wilhelm (2013)
10.5772/26987
microRNAs as Therapeutic Targets to Combat Diverse Human Diseases
Elizabeth Hong-Geller (2011)
Intracellular drug delivery using laser activated carbon nanoparticles
Aritra Sengupta (2014)
Office of Cancer Nanotechnology Research Center for Strategic Scientific Initiatives (CSSI)
(2011)
10.1016/j.nano.2015.12.361
Ultrasound-responsive microbubbles for sonography-guided siRNA delivery.
P. Wang (2016)
NANOPARTICLES: STATE-OF-THE- ART AND REMAINING CHALLENGES
Gaurav Bajaj (2013)
10.1007/978-3-642-38815-6_9
Nano-encapsulation of Oligonucleotides for Therapeutic Use
Eveline E. Salcher (2014)
10.1021/NN3030223
Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing.
João Conde (2012)
10.1111/j.1748-720X.2012.00705.x
A Portrait of Nanomedicine and its Bioethical Implications
Rebecca M. Hall (2012)
10.1007/7355_2015_95
Personalized Medicine: Where Do We Go from Here?
Dipanjan Pan (2015)
10.1039/c5cc05242d
A biodegradable adamantane polymer with ketal linkages in its backbone for gene therapy.
Santanu Maity (2015)
10.1039/C5TB01602A
RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay.
Chunying Cui (2015)
10.13023/ETD.2017.272
EFFECTS OF CORE AND SHELL MODIFICATION TO TETHERED NANOASSEMBLIES ON SIRNA THERAPY
Steven Rheiner (2017)
10.5772/58488
Src Family Kinases in Intracerebral Hemorrhage
Dazhi Liu (2014)
10.1002/9780470015902.A0021020.PUB2
Gene Inactivation Strategies: An Update
Chang-an Guo (2014)
10.1007/978-3-319-17903-2_3
Molecular Biology of Kidney Cancer
William G. KaelinJr. (2012)
10.1016/j.canlet.2011.10.007
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.
J. H. Trembley (2012)
10.1016/j.ejpb.2018.02.023
Development of controlled drug delivery systems for bone fracture‐targeted therapeutic delivery: A review
Yuchen Wang (2018)
10.1021/acs.molpharmaceut.0c00714
Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.
E. Kwon (2020)
10.1021/MA402081H
Supramolecular Linear-g-Hyperbranched Graft Polymers: Topology and Binding Strength of Hyperbranched Side Chains
Christian M. Moers (2013)
10.1038/srep07471
Recycling Gene Carrier with High Efficiency and Low Toxicity Mediated by L-Cystine-Bridged Bis(β-cyclodextrin)s
Yu-hui Zhang (2014)
10.1016/j.peptides.2013.12.014
DsRNA degradation in the pea aphid (Acyrthosiphon pisum) associated with lack of response in RNAi feeding and injection assay
O. Christiaens (2014)
10.1016/j.canlet.2016.03.045
Challenges and opportunities for siRNA-based cancer treatment.
Tao Wang (2017)
10.1016/j.ejpb.2015.03.018
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
10.1016/j.biomaterials.2013.10.019
Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.
Szu-Ting Chou (2014)
10.1517/14728222.2013.840293
Targeting ribonucleotide reductase for cancer therapy
J. Shao (2013)
ADVANCES IN TRANSLATIONAL SCIENCE
J. Sellin (2012)
10.1016/j.jconrel.2011.04.029
Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes.
X. Ming (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar